A detailed history of Clark Financial Services Group Inc transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Clark Financial Services Group Inc holds 13,872 shares of TGTX stock, worth $337,921. This represents 0.26% of its overall portfolio holdings.

Number of Shares
13,872
Previous 13,911 0.28%
Holding current value
$337,921
Previous $211,000 16.59%
% of portfolio
0.26%
Previous 0.25%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$13.32 - $19.19 $519 - $748
-39 Reduced 0.28%
13,872 $246,000
Q1 2024

May 14, 2024

SELL
$13.02 - $21.3 $5,793 - $9,478
-445 Reduced 3.1%
13,911 $211,000
Q4 2023

Feb 14, 2024

BUY
$6.68 - $18.81 $1,075 - $3,028
161 Added 1.13%
14,356 $246,000
Q3 2023

Nov 13, 2023

BUY
$8.36 - $26.5 $15,549 - $49,290
1,860 Added 15.08%
14,195 $118,000
Q2 2023

Aug 14, 2023

SELL
$15.48 - $35.0 $76,486 - $172,935
-4,941 Reduced 28.6%
12,335 $306,000
Q1 2023

May 12, 2023

SELL
$10.23 - $19.34 $5,626 - $10,637
-550 Reduced 3.09%
17,276 $260,000
Q4 2022

Feb 14, 2023

BUY
$5.01 - $11.83 $3,116 - $7,358
622 Added 3.62%
17,826 $210,000
Q3 2022

Nov 14, 2022

BUY
$4.57 - $8.4 $9,990 - $18,362
2,186 Added 14.56%
17,204 $102,000
Q1 2022

May 13, 2022

SELL
$7.81 - $20.45 $343 - $899
-44 Reduced 0.29%
15,018 $143,000
Q4 2021

Feb 10, 2022

SELL
$15.2 - $35.51 $1,717 - $4,012
-113 Reduced 0.74%
15,062 $286,000
Q3 2021

Nov 12, 2021

BUY
$21.78 - $40.45 $3,179 - $5,905
146 Added 0.97%
15,175 $505,000
Q2 2021

Aug 09, 2021

BUY
$32.5 - $48.96 $1,462 - $2,203
45 Added 0.3%
15,029 $583,000
Q1 2021

May 17, 2021

SELL
$41.61 - $54.3 $110,016 - $143,569
-2,644 Reduced 15.0%
14,984 $722,000
Q2 2020

Aug 12, 2022

BUY
$8.9 - $21.84 $156,889 - $384,995
17,628 New
17,628 $75,000

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $3.54B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Clark Financial Services Group Inc Portfolio

Follow Clark Financial Services Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clark Financial Services Group Inc , based on Form 13F filings with the SEC.

News

Stay updated on Clark Financial Services Group Inc with notifications on news.